That’s fine as long as the equity acquirers don’t dump on the market again!
Just can’t tolerate that so much effort from the mgmt and BOD doesn’t seem to get reflected in the SP, not that it is a perfect yardstick. While BP may be interested in the revenue generating potential of Zantrene based on trial success, would they offer 10X of SP if we are stuck in single digit dollars though annual revenue generating potential could be $XX Bn? Frustrating, to say the least.
General Comments / Chat, page-4130
-
- There are more pages in this discussion • 7,692 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |